Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JHM03 for Moderate to Severe Glabellar Lines (Phase I/II, China)
CTR20234169Phase 2Completed
- Sponsor
- Junhe Alliance Biopharmaceutical
- Start
- Dec 2023
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of JHM03 in glabellar furrowing, sponsored by Junhe Alliance Biopharmaceutical. Started Dec 2023; status: completed.
02
Drugs
JHM03
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on CTR20234169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234169.